530 related articles for article (PubMed ID: 18517081)
1. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
Esch RE; Bush RK; Peden D; Lockey RF
Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
[TBL] [Abstract][Full Text] [Related]
2. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
[TBL] [Abstract][Full Text] [Related]
4. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
5. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules - IPD meta-analysis.
Sieber J; Köberlein J; Mösges R
Curr Med Res Opin; 2010 Apr; 26(4):925-32. PubMed ID: 20163297
[TBL] [Abstract][Full Text] [Related]
7. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.
Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R
Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808
[TBL] [Abstract][Full Text] [Related]
8. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
Allergy; 2009 Sep; 64(9):1394-401. PubMed ID: 19764942
[TBL] [Abstract][Full Text] [Related]
11. [New administration routes for immunotherapy].
Martorell Aragonés A
Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
[TBL] [Abstract][Full Text] [Related]
12. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units.
Larenas-Linnemann D; Esch R; Plunkett G; Brown S; Maddox D; Barnes C; Constable D
Ann Allergy Asthma Immunol; 2011 Nov; 107(5):448-458.e3. PubMed ID: 22018618
[TBL] [Abstract][Full Text] [Related]
13. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
Kleine-Tebbe J; Ribel M; Herold DA
Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
15. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS
J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
[TBL] [Abstract][Full Text] [Related]
16. Rush sublingual immunotherapy in Parietaria allergic patients.
D'Ambrosio FP; Ricciardi L; Isola S; Savi E; Parmiani S; Puccinelli P; Musarra A
Allergol Immunopathol (Madr); 1996; 24(4):146-51. PubMed ID: 8939269
[TBL] [Abstract][Full Text] [Related]
17. Advances in upper airway diseases and allergen immunotherapy.
Nelson HS
J Allergy Clin Immunol; 2007 Apr; 119(4):872-80. PubMed ID: 17292953
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
Gammeri E; Arena A; D'Anneo R; La Grutta S
Allergol Immunopathol (Madr); 2005; 33(4):221-3. PubMed ID: 16045861
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
